China Medical System Holdings Limited Announces Acceptance of New Drug Application for MG-K10 in China

Key Highlights

• China Medical System Holdings Limited (CMS) has announced that the National Medical Products Administration of China (NMPA) has accepted the New Drug Application (NDA) for MG-K10, a Class 1 innovative drug for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR).
• MG-K10 is a long-acting anti-IL-4Rα humanized monoclonal antibody injection, targeting type 2 inflammatory diseases. The Group holds co-development rights (excluding atopic dermatitis) and exclusive commercialization rights for MG-K10.
• The NDA was officially accepted by NMPA on 23 April 2026. The product is proposed for adult patients whose SAR symptoms are inadequately controlled after treatment with intranasal corticosteroids.

MG-K10: Innovative Therapy with Differentiated Advantages

• MG-K10 simultaneously blocks IL-4 and IL-13 signaling pathways, which are central to type 2 inflammatory diseases including SAR, asthma, atopic dermatitis, prurigo nodularis, COPD, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
• Unlike current anti-IL-4Rα therapies that require bi-weekly administration, MG-K10 offers a once-monthly (every four weeks) dosing regimen due to its longer half-life, potentially making it the first long-acting anti-IL-4Rα monoclonal antibody available globally and a best-in-class contender.
• MG-K10 successfully met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adults with moderate-to-severe SAR, demonstrating statistically significant superior efficacy and a favorable safety profile.

Market Opportunity and Unmet Clinical Needs

• Allergic rhinitis has a rising prevalence in China, affecting an estimated 250 million people, with over half (52.2%) suffering from persistent moderate-to-severe disease.
• Current therapies, including intranasal corticosteroids and antihistamines, show considerable limitations. 62% of patients with moderate-to-severe SAR remain inadequately controlled.
• Long-term corticosteroid use carries risks (e.g., epistaxis), while antihistamines cause undesirable side effects (e.g., drowsiness).
• MG-K10, as a biologic targeting IL-4Rα, addresses these unmet needs by blocking the inflammatory pathway at its source and extending dosing intervals, which may improve patient adherence and reduce healthcare costs and hospital visits.

Strategic and Business Implications

• The NDA acceptance for MG-K10 marks a milestone for CMS’s ophthalmology business (CMS Vision), signaling an expansion into otolaryngology (ENT) and reinforcing the Group’s presence in type 2 inflammatory disease R&D.
• Upon successful approval, CMS intends to leverage its robust academic promotion and commercialization network to accelerate product launch and further strengthen its brand influence in relevant specialty areas.
• MG-K10 represents a significant growth driver for CMS, providing momentum for future business expansion.

Collaboration and Commercialization Rights

• On 24 January 2025, CMS entered into a Collaboration Agreement with Hunan Mabgeek Biotech Co., LTD and its subsidiary. Under this agreement and supplementary agreements, CMS secured co-development rights (excluding atopic dermatitis) and exclusive commercialization rights for MG-K10 in Mainland China, Hong Kong, Macao, Taiwan, and Singapore.
• CMS’s subsidiary, Dermavon Holdings Limited, also obtained rights for dermatological indications in Mainland China.

Potential Price-Sensitive Information for Shareholders

• The acceptance of the NDA by NMPA is a key regulatory milestone that could significantly affect CMS’s share price, especially if MG-K10 is approved and commercialized successfully.
• MG-K10’s differentiated dosing regimen and best-in-class potential position it as a disruptor in the SAR treatment landscape, which could drive substantial revenue growth and market share gains for CMS.
• Investors should note that while the NDA acceptance is promising, approval, commercialization, and market uptake remain subject to regulatory and operational risks.

Board and Management

• The board of CMS is chaired by Mr. Lam Kong, with Ms. Chen Yanling, Mr. Leung Chong Shun, Ms. Luo Laura Ying, and Mr. Fung Ching Simon serving as executive and independent non-executive directors.

Investor Guidance

The announcement is made on a voluntary basis. Shareholders and investors are advised to exercise caution in dealing in the shares and other securities of the Company.

Disclaimer: The information in this article is intended for informational purposes only and should not be construed as investment advice. Investors should conduct their own research and consult with professional advisors before making investment decisions. The acceptance of NDA is not equivalent to regulatory approval, and there remain risks associated with clinical development, regulatory outcomes, and commercialization.

View CMS Historical chart here